Article Versions Notes

Usero L, Leal L, Gómez CE, Miralles L, Aurrecoechea E, Esteban I, Torres B, Inciarte A, Perdiguero B, Esteban M, et al. The Combination of an mRNA Immunogen, a TLR7 Agonist and a PD1 Blocking Agent Enhances In-Vitro HIV T-Cell Immune Responses. Vaccines. 2023; 11(2):286. https://doi.org/10.3390/vaccines11020286

Usero, Lorena, Lorna Leal, Carmen Elena Gómez, Laia Miralles, Elena Aurrecoechea, Ignasi Esteban, Berta Torres, Alexy Inciarte, Beatriz Perdiguero, Mariano Esteban, and et al. 2023. "The Combination of an mRNA Immunogen, a TLR7 Agonist and a PD1 Blocking Agent Enhances In-Vitro HIV T-Cell Immune Responses" Vaccines 11, no. 2: 286. https://doi.org/10.3390/vaccines11020286

Usero, L., Leal, L., Gómez, C. E., Miralles, L., Aurrecoechea, E., Esteban, I., Torres, B., Inciarte, A., Perdiguero, B., Esteban, M., García, F., & Plana, M. (2023). The Combination of an mRNA Immunogen, a TLR7 Agonist and a PD1 Blocking Agent Enhances In-Vitro HIV T-Cell Immune Responses. Vaccines, 11(2), 286. https://doi.org/10.3390/vaccines11020286